Investigational drug · Phase 2
SOT109
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Cancer (Locally Advanced or Metastatic).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SOT109"
First trial start
2026
Aug 12, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SOT109", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer (Locally Advanced or Metastatic)
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SOT109" as an intervention, largest first.
- A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal CancerPivotal-lookingRecruiting
SOTIO Biotech a.s.Industry
NCT07693751 · 100 participants (planned) · Start Aug 12, 2026 · Primary completion Nov 29, 2027
Drug: SOT109 · For: Colorectal Cancer (Locally Advanced or Metastatic)
Sites: Houston, Texas; Fairfax, Virginia; Brno, Czechia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.